The fact that navitoclax has been shown to enhance sensitivity of paediatric glioma to metformin113 or in several p53‐defective cells previously114 reinforces a promising role of metformin in sensitising navitoclax effect in cancer treatment. Here, TP53 is linked to central nervous system cancer.